Difference between revisions of "Eluvixtamab (AMG-330)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
||
| Line 4: | Line 4: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Chemotherapeutic]] | [[Category:Chemotherapeutic]] | ||
| − | [[Category: | + | [[Category:Immunotherapeutic]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 17:46, 3 February 2019
Mechanism of action
Bispecific T-cell engager (BiTE) antibody that engages CD33 and CD3